Dana-Farber researchers are evaluating strategies to improve the CAR T-cell product to enhance efficacy and safety, study novel antigens, and use these therapies in earlier disease states, including newly-diagnosed MM and high-risk smoldering myeloma.
A small percentage of cancers are due to inherited genetic (or germline) mutations, which can often be identified through genetic testing.
One of the goals of the Ending Metastatic Breast Cancer for Everyone (EMBRACE) program at Dana-Farber Cancer Institute is to provide resources and information to…
Explore the role of clinical trials in evaluating new cancer treatments and their importance in patient care and drug approval.
Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival…
Published: April 10, 2025Written by: Dana-Farber Editorial TeamMedical advances tend to unfold slowly over many years, fueled by successive clinical studies that build upon each…
Could microplastics be contributing to cancer risk? Uncover the findings related to colorectal cancer in young adults and pollution.
Natural killer (NK) cells have specialized roles as part of the immune system and have shown potential for being used in cancer immunotherapy.
Published: February 6, 2025Written by: Beth DoughertyMedically Reviewed By: Atish Choudhury, MD, PhD, Toni Choueiri, MD, and Mark Pomerantz, MDDana-Farber’s genitourinary cancer team is devoted…
At Dana-Farber, our experts are looking at ultraprocessed foods and their association with cancer risks from multiple angles.
Misinformation about science and health can lead individuals to make ill-informed decisions that aren’t in their best interest.
